Published in Gene Therapy Weekly, December 28th, 1998
CML is a pluripotent hematopoietic stem cell disease. Several research groups have studied antisense-based therapeutic approaches to this disease. However, despite progress, antisense approaches for CML remain controversial.
Avudaiappan Maran, Cornelius F. Waller, and a team of researchers from the U.S. National Institutes of Health, and the Cleveland Clinic Foundation, Ohio, examined a novel antisense oligonucleotide (ODN) approach in vitro ("2',5'-Oligoadenylate-Antisense Chimeras Cause RNase L to Selectively Degrade...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly